search
Disc Medicine
Trends
- 1
Disc Medicine, a clinical-stage biotech company, is facing investor investigations following an FDA letter that raised concerns for shareholders. Law firms have reportedly begun looking into whether the company misled investors about its regulatory prospects. The development puts pressure on the stock and adds uncertainty to the company's drug approval timeline, drawing attention from biotech investors tracking FDA-related setbacks.
- 2Bank of America Builds $9.88 Million Stake in Disc Medicine●Bank of America Corp DE Makes New $9.88 Million Investment in Disc Medicine, Inc. $IRON
Bank of America Corp DE has disclosed a new position worth $9.88 million in Disc Medicine, Inc., the biotech company traded under the ticker IRON. The filing reveals the bank took a fresh stake in the clinical-stage firm, whose stock is often followed by institutional investors in the biotechnology sector.